Incretin Hormone & Insulin Secretion Regulation
Glucagon-Like Peptide-1 (7-36 amide)
Glucagon-Like Peptide-1 (GLP-1) is a 30-amino-acid incretin hormone produced by L-cells in the distal small intestine and colon in response to nutrient ingestion. It is derived from the proglucagon gene through tissue-specific post-translational processing and plays a central role in the regulation of glucose homeostasis, insulin secretion, and appetite.
GLP-1 is the parent molecule of an entire class of FDA-approved diabetes and obesity medications — the GLP-1 receptor agonists — including semaglutide (Ozempic®, Wegovy®), liraglutide (Victoza®), and tirzepatide. Research on native GLP-1 continues to be foundational for understanding the pharmacology of this drug class and for developing next-generation metabolic therapeutics.
GLP-1 (7-36 amide) is the biologically active form of GLP-1, consisting of 30 amino acids (residues 7–36 of the full proglucagon-derived peptide) with a C-terminal amide group. The amide group is essential for full GLP-1 receptor binding activity. The molecular weight is 3,297.7 Daltons.
Native GLP-1 has an extremely short half-life of approximately 1–2 minutes in vivo due to rapid cleavage by dipeptidyl peptidase IV (DPP-IV) at the His⁷-Ala⁸ bond, and by neutral endopeptidase (NEP). This rapid degradation is the primary limitation of native GLP-1 as a therapeutic agent and has driven the development of DPP-IV-resistant analogs.
GLP-1 exerts its primary effects by binding to the GLP-1 receptor (GLP-1R), a class B G-protein coupled receptor expressed on pancreatic beta cells, the gastrointestinal tract, the heart, kidneys, and the central nervous system. GLP-1R activation stimulates adenylyl cyclase via Gαs, increasing intracellular cAMP levels and activating both PKA and EPAC (exchange protein directly activated by cAMP) signaling pathways.
In pancreatic beta cells, this cascade potentiates glucose-stimulated insulin secretion (GSIS) in a glucose-dependent manner — a critical safety feature that means GLP-1 only stimulates insulin release when blood glucose is elevated, minimizing hypoglycemia risk. GLP-1 also inhibits glucagon secretion from alpha cells, slows gastric emptying, and acts on hypothalamic GLP-1R to reduce appetite and food intake.
GLP-1 (Glucagon-Like Peptide-1) is a hormone your gut naturally releases after you eat. It's the biological signal behind some of the most talked-about drugs in medicine right now — semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) are both designed to mimic or enhance GLP-1's effects. The research-grade GLP-1 peptide itself is the native molecule those drugs are based on.
GLP-1 works through three main mechanisms: it tells the pancreas to release insulin when blood sugar is high (glucose-dependent, meaning it won't cause hypoglycemia when blood sugar is normal), it suppresses glucagon (the hormone that raises blood sugar), and it slows gastric emptying — meaning food leaves your stomach more slowly, which reduces appetite and blunts post-meal blood sugar spikes. It also acts on the brain's appetite centers to reduce hunger signals.
GLP-1 is at the center of one of the most significant breakthroughs in metabolic medicine in decades. The GLP-1 receptor agonist drug class has demonstrated not just blood sugar control and weight loss, but also cardiovascular risk reduction and potential neuroprotective effects. Understanding the native GLP-1 peptide is foundational to this entire research area.
GLP-1 is the native hormone that the entire GLP-1 agonist drug class (Ozempic, Wegovy, Mounjaro) is built around. The research-grade peptide supplied by Purgo Labs has a very short half-life (~2 minutes) compared to pharmaceutical analogs, making it a precise research tool for studying GLP-1 receptor biology. For laboratory research use only.
Activates GLP-1R on beta cells, stimulating adenylyl cyclase → cAMP → PKA/EPAC cascade that potentiates glucose-stimulated insulin secretion.
Insulin secretion is potentiated only in the presence of elevated blood glucose, providing an inherent safety mechanism against hypoglycemia.
Inhibits alpha cell glucagon secretion, reducing hepatic glucose output and contributing to postprandial glucose control.
Hypothalamic GLP-1R activation reduces food intake and body weight through central satiety signaling pathways.
Metabolic Research
≥99% purity · Third-party tested
Use code Health for 15% off
Fast FedEx shipping · 60-day guarantee
| Peptide Class | Incretin hormone (30 amino acids, C-terminal amide) |
| Molecular Weight | 3,297.7 Da |
| Receptor Target | GLP-1 receptor (GLP-1R) — class B GPCR |
| Half-life (native) | ~1–2 minutes (DPP-IV and NEP cleavage) |
| Drug Class Progenitor | Semaglutide, liraglutide, tirzepatide |
| Available Sizes | 5mg vials |
| Form | Lyophilized powder |
| Purity | ≥99% (third-party tested) |
View full legal status guide →
Purgo Labs offers GLP-1 with ≥99% purity, third-party certificates of analysis, and fast FedEx shipping. This is an affiliate link — we may earn a commission at no cost to you.
Purchase GLP-1 at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.
